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Oxidative stress is widely known to play a role in asthma.  However,  the contribution of xanthine 
oxidoreductase (XOR) as a source of the superoxide anion radical (O2－) in oxidative stress associated 
with asthma has not yet been examined in detail.  Here we investigated pathophysiological changes in 
XOR in an experimental model of asthma induced by the house dust mite Dermatophagoides farinae 
(Df).  In the lungs of Df-treated mice,  the production of O2－ from XOR increased and the nitrite con-
centrations decreased,  whereas the protein expression of XOR remained unchanged.  Moreover,  the 
protein expression levels of XOR and the hydrogen peroxide (H2O2) concentrations in bronchoalveolar 
lavage ﬂuid (BALF) were higher in the Df-treated mice than in saline-treated mice.  Immunohistochem-
ically,  although XOR was highly localized in the bronchial epithelial cells of the saline-treated mice,  
immunostaining for XOR was absent in the bronchial epithelium of Df-treated mice.  These results 
suggest that oxidative stress is up-regulated by increases in the conversion of the dehydrogenase form 
(xanthine dehydrogenase; XDH) of XOR to the oxidase form (xanthine oxidase; XOD).
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G enerally,  oxidative stress represents the imbal-ance of the up-regulated generation of reactive 
oxygen species (ROS) and the anti-oxidative defense 
system.  In asthma,  the following have been demon-
strated: increased ROS by the up-regulated activity of 
the NADPH (nicotinamide adenine dinucleotide phos-
phate) oxidase complex in macrophages,  neutrophils 
and eosinophils [1],  mitochondrial dysfunction in 
airway epithelial cells [2],  and decreased levels of 
anti-oxidative systems such as superoxide dismutase,  
catalase and glutathione peroxidase and reduced form 
of glutathione [3].  Although nitric oxide synthase 
(NOS) II is up-regulated in asthma [4],  nitric oxide 
(NO) generation to neutralize superoxide anion radical 
(O2－) was decreased by the induction of arginase I,  
which consumes  L-arginine as a common substrate of 
NOS and arginase I [5-8].  The origins of superoxide 
(O2－) are generally said to be the NADPH oxidase 
complex,  the mitochondrial electron transport system,  
and xanthine oxidase.  However,  as an origin of O2－ in 
oxidative stress in asthma,  the involvement of xan-
thine oxidase in asthma has not been investigated,  to 
our knowledge.
　 Xanthine oxidoreductase (XOR) is a homodimer of 
approx.  290 kD.  The oxidase form of XOR,  xanthine 
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oxidase (XOD),  is well known for its ability to pro-
duce O2－ in the presence of hypoxanthine [9-11].  In 
mammalian cells in the physiological condition,  the 
dehydrogenase form of XOR,  xanthine dehydrogenase 
(XDH),  is dominant,  and its substrate-derived elec-
trons reduce NAD+ to NADH [12].  It was suggested 
that under ischemia or inﬂammation,  XDH converts to 
XOD by the reaction of oxygen radicals [13,  14].  
However,  from the previous research indicates that 
the conversion of XDH to XOD occurs through limited 
proteolysis [15] or a reversible oxidation of disulﬁde 
bonding between cysteine 535 and cysteine 992 [16].  
After the conversion of XDH to XOD,  when the aﬃn-
ity for NAD+ to XOD at the FAD on XOD is greatly 
decreased,  the aﬃnity for oxygen to XOD is enhanced,  
resulting in the generation of O2－ or hydrogen perox-
ide (H2O2) by 1 or 2 electron transfers [17].
　 Moreover,  the C-terminal peptide contains hydro-
phobic and positively charged amino acids,  and it 
could interact with other proteins or membranes,  
thereby shifting the XDH to XOD and the intermedi-
ate form of XOR [16].  Physiological roles for the 
observed XDH to XOD transition have been proposed 
for lactation in mammals,  in which the XOR in milk 
has an antimicrobial function by generating NO from 
NO2－ [18].  XOR has a property of nitrite reductase,  
in which NO2－ is reduced to NO under anoxic and 
acidic conditions [19,  20].  From the viewpoint of the 
partial conversion of XDH to XOD,  the so-called 
“intermediate form of XOR” in physiological condi-
tions [16],  and the actual conversion of XDH to XOD 
during experimental preparations of tissues such as 
freezing and homogenization [13],  it is diﬃcult to 
distinguish XDH and XOD.  Therefore,  in the present 
study,  we used XOR instead of XDH or XOD unless 
otherwise speciﬁed.
　 We investigated the involvement of XOR in asthma 
of NC/Nga mice induced by the house dust mite 
Dermatophagoides farinae (Df).
Materials and Methods
　 Animals. Male NC/Nga mice (7 weeks old,  8 
mice/group) were obtained from Charles River 
Laboratories Japan (Yokohama,  Japan).  The mice 
were maintained under speciﬁc pathogen-free condi-
tions with a 12-h light/dark cycle and had free access 
to standard laboratory food and tap water.  They were 
acclimatized for at least 1 week before the experi-
ment.  The care and handling of the mice were per-
formed in accord with the Guidelines for the Care and 
Use of Laboratory Animals at the Shikata Campus of 
Okayama University and approved by the Okayama 
University Institutional Animal Care and Use 
Committee.
　 Induction of asthma. A mite crude extract 
from Df (Cosmo Bio,  Tokyo,  Japan) was intranasally 
administered to NC/Nga mice as described [7,  8,  
21].  Brieﬂy,  50μg of the Df extract dissolved in 25μl 
of saline was administered on 5 consecutive days (days 
0-4) by intranasal instillation under anesthesia with 
40mg/kg of sodium pentobarbital (Kyoritsu Seiyaku,  
Tokyo,  Japan).  On day 11,  a single challenge with 50μg 
of Df in 25μl of saline was administered intranasally 
under anesthesia.  In the control group,  25μl of saline 
was aministered in the same manner.
　 Collection of bronchoalveolar lavage ﬂuid 
(BALF) and lung tissue. On day 14,  the mice 
were sacriﬁced by bleeding under anesthesia,  and the 
lung was lavaged with 1ml of Hankʼs Balanced Salt 
Solution (HBSS) via a tracheal cannula while the 
thorax was gently massaged.  The ﬂuid collected was 
centrifuged at 200g,  and the supernatant was taken as 
bronchoalveolar lavage ﬂuid (BALF).  After the lavage,  
lung tissue was removed.  The BALF and lung tissue 
were used in the subsequent experiments.
　 Tissue sample preparation for analysis.
BALF was mixed with ice-cold acetone and methanol 
(8 : 2),  kept on ice for 90min,  and then centrifuged at 
2,800g at 4℃ for 15min in order to precipitate pro-
teins.  The pellet obtained was dissolved in phosphate-
buﬀered saline (PBS).
　 Lung tissue was homogenized in lysis buﬀer 
(20mM Tris-HCl pH7.5,  150mM NaCl,  1mM EDTA,  
and 1  Triton X-100) containing complete proteinase 
inhibitor cocktail (Roche,  Mannheim,  Germany),  and 
then ultracentrifuged at 105,000g for 60min at 4℃.  
The lysates were then harvested.  The total protein 
concentrations in the samples were measured using the 
BCA Protein Assay Kit (Thermo Fisher Scientiﬁc,  
Rockford,  IL,  USA).  Samples were stored at －80℃ 
until used.
　Western blot analysis. Protein samples were 
adjusted to 15μg (BALF) and 30μg (lung) of protein in 
sample buﬀer (62.5mM Tris-HCl pH6.8,  2  sodium 
dodecyl sulfate [SDS],  10  glycerol,  2  dithioth-
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reitol,  and 0.02  bromophenol blue),  and then boiled 
for 5min to denature the proteins.  These samples 
were separated on SDS-polyacrylamide gels,  trans-
ferred onto polyvinylidene diﬂuoride (PVDF) mem-
branes (Millipore,  Bedford,  MA,  USA) in Tris-
Glycine-Methanol Transfer buﬀer,  and blocked in 5  
non-fat dried milk in Tris-buﬀered saline containing 
0.05  Tween-20 (TBST).  The membranes were then 
incubated with a rabbit anti-XOD antibody (1 : 400) 
(Santa Cruz Biotechnology,  Dallas,  TX,  USA) as the 
primary antibody at 4℃ overnight.  An anti-β tubulin 
antibody (1 : 10,000) (Abcam,  Cambridge,  UK) was 
used as the loading control.  The membranes were then 
washed in TBST and incubated at room temperature 
for 1h with a horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit IgG antibody.  The membranes were 
washed in TBST and protein bands were visualized on 
X-ray ﬁlms (Eastman Kodak,  Rochester,  NY,  USA) 
with Western Lightning Ultra for XOD detection or 
Western Lightning Plus-ECL reagents (Perkin-
Elmer,  Boston,  MA,  USA) for GAPDH detection.  
The expression level of XOD was quantiﬁed by 
ImageJ software (U.S.  National Institutes of Health,  
Bethesda,  MD,  USA) and normalized with that of 
GAPDH.
　 Immunostaining for XOR. Lung tissue was 
immersed in 10  neutral-buﬀered formalin and embed-
ded in paraﬃn.  Paraﬃn-embedded lung tissue was 
sliced to a thickness of 4μm.  Deparaﬃnized lung tis-
sue slices were incubated in methanol containing 1  
H2O2 at room temperature for 30min in order to 
inactivate endogenous peroxidase,  then washed with 
TBS and incubated in 5  normal goat serum (Wako,  
Osaka,  Japan) at room temperature for 1h to block 
nonspeciﬁc binding.  Specimens were incubated over-
night with a primary antibody (rabbit anti- XOD anti-
body,  dilution 1 : 200,  Santa Cruz Biotechnology) at 
4℃ followed by a biotinylated secondary antibody 
(goat anti-rabbit IgG conjugated with a peroxidase-
labeled dextran polymer,  Dako,  Glostrup,  Denmark) 
at room temperature for 1h.  Color was developed 
with 3,3-diaminobenzidine tetrahydrochloride (Dako) 
as a substrate and counterstained with hematoxylin 
(Merck Millipore,  Darmstadt,  Germany) [22].  Rabbit 
non-immune immunoglobulin (Dako) was used as a 
negative control.
　 Measurement of XOR activity by O2－ produc︲
tion. XOR activity was analyzed by zymography,  
which detects nitro blue tetrazolium (NBT) reduction 
to formazan by O2－ under conditions in which the 
eﬀect of superoxide dismutase is removed in the tis-
sue,  as described [23].  Lung homogenates were mixed 
in sample buﬀer (62.5mM Tris-HCl pH6.8,  10  
glycerol,  and 0.02  bromophenol blue) and subjected 
to native polyacrylamide gel electrophoresis (PAGE).  
Gels were immersed in 50mM phosphate buﬀer 
(pH7.8),  150μM xanthine,  and 0.02  NBT (Sigma,  
St Louis,  MO,  USA),  and gently rocked for 40min 
at room temperature.  A visualized band for blue 
formazan on the gel,  which was generated by the 
reduction of NBT with O2－,  was quantiﬁed by ImageJ 
software and compared with the saline group.  To 
ascertain the non-speciﬁc reduction of NBT,  we added 
excess bovine Cu and Zn-superoxide dismutase (Wako) 
to the reaction.
　 Measurement of XDH activity using NADH 
formation. We measured the XDH activity in the 
lung by evaluating the generation of NADH from 
NAD+ in the presence of xanthine using the ﬂuores-
cence of NADH.  Lung homogenates were mixed in 
50mM phosphate buﬀer (pH7.8),  0.1mM diethylene-
triamine-N,N,N’,N”,N”-pentaacetic acid (DTPA),  
0.5mM NAD+,  and 360μM xanthine.  The reaction was 
initiated by the addition of xanthine at 25℃,  and we 
monitored changes in intensity due to the generation of 
NADH using a 650-10 LC ﬂuorescence detector 
(Hitachi,  Tokyo,  Japan) (excitation/emission 
wavelengths: 340/460nm).  The production of NADH 
was qualiﬁed by using commercially available NADH 
(Oriental Yeast,  Tokyo,  Japan).  The XDH activity is 
represented as nmol of NADH/min/mg protein.
　 Measurement of uric acid. We measured the 
uric acid concentrations in the lung tissue using the 
LabAssay Uric Acid Kit according to the manufac-
turerʼs protocol (Wako).  Uric acid concentrations 
were normalized by the protein content.
　 Measurement of H2O2. We determined the 
H2O2 level in the BALF by monitoring decreases in the 
ﬂuorescence of scopoletin oxidized by HRP,  as 
described by Corbett et al.  [24].  BALF was added to 
HBSS containing 2.4μM scopoletin (Sigma) and 
0.5μg/ml HRP (Wako) in microplates.  Fluorescent 
measurements before the addition of BALF were 
obtained using a Flex Station 3 ﬂuoro-microplate 
reader (Molecular Devices,  Sunnyvale,  CA,  USA) 
(excitation/emission wavelengths: 355/460nm).  
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Twenty min after the incubation with the sample at 
room temperature,  ﬂuorescence was read again at the 
same wavelength.  A standard curve was made using 
commercially available H2O2 (Wako).
　 Measurement of nitrite (NO2－) and nitrate 
(NO3－). We measured the NO2－ and NO3－ concen-
trations in the lung tissue and BALF by the ozone-
chemiluminescence method using a NO analyzer 
(Model-280i NOA with a Purge Vessel; Sievers,  
Boulder,  CO,  USA) [8,  25].  Brieﬂy,  for deprotein-
ization,  lung tissue homogenates without 1  Triton 
X-100 or BALF were added with the same volume of 
acetonitrile and centrifuged at 15,000g.  The NO2－ in 
the supernatant was further reduced to NO in a purge 
vessel ﬁlled with the reducing agent (potassium iodide 
solution in acetic acid with argon gas).  In order to 
determine NOx (NO2－ and NO3－),  we treated the 
supernatants with nitrate reductase (Sigma) at room 
temperature for 30min in order to convert NO3－ to 
NO2－.  NO was detected as chemiluminescence,  and the 
NO3－ concentrations were calculated by subtracting 
the NO2－ concentrations from the NOx concentrations.
　 Statistical analysis. Data are expressed as the 
mean ± standard error (SE) and were analyzed by 
Studentʼs unpaired t-test.  P-values ＜0.05 were consid-
ered signiﬁcant.  Statistical analyses were performed 
using GraphPad Prism ver 6.07 (GraphPad Software,  
San Diego,  CA,  USA).
Results
　 XOR expression in lung tissue and BALF.
The protein expression of XOR in the lung tissue and 
BALF was analyzed by western blotting.  No signiﬁ-
cant diﬀerence was observed in the expression of XOR 
in lung tissue between the saline- and Df-treated mice 
(Fig.  1A).  In contrast,  the protein expression level of 
XOR in the BALF was signiﬁcantly higher in the 
Df-treated mice compared to the saline-treated mice 
(p＜0.001) (Fig.  1B).
　 Localization of XOR in lung tissue. The 
localization of XOR in the lung tissue was observed by 
immunohistochemistry.  Strong intensity was observed 
in bronchial epithelial cells in the lung tissue of the 
saline-treated mice (Fig.  2A).  In addition,  small 
droplet-like immunostaining was observed in the air-
way lumen.  In the lungs of the Df-treated mice,  the 
immunostaining for XOR was weak in bronchial epi-
thelial cells (Fig.  2B).
　 XOR activity in lung tissue. The XOR activ-
ity in lung tissue was measured by zymography based 
on the capacity to generate O2－ because superoxide 
dismutase was included in the tissue.  The XOR activ-
ity was stronger in the Df-treated mice than in the 
saline-treated mice (Fig.  3).
　 XDH activity in lung tissue. We measured 
the activity of XDH based on the formation of NADH 
from NAD+ in the presence of xanthine.  No signiﬁcant 
diﬀerence was observed in XDH activity between the 
saline- and Df-treated mice (Fig.  4).
　 Uric acid concentrations in BALF and lung 
tissue. Uric acid was not detected in the BALF of 
the Df-treated mice or the saline-treated mice.  However,  
the uric acid concentrations in the lungs were signiﬁ-
cantly higher in the Df-treated mice than in the saline-
treated mice (p＜0.05) (Fig.  5).
　 H2O2 concentrations in BALF. No signiﬁcant 
diﬀerences were observed in the concentration of H2O2 
in lung tissue between the saline- and Df-treated mice 
(Fig.  6A),  whereas the concentration of H2O2 in the 
BALF was signiﬁcantly higher in the Df-treated mice 
than in the saline-treated mice (p＜0.05) (Fig.  6B).
　 NO2－ and NO3－ concentrations in lung tissue.
The concentration of NO2－ in lung tissue was signiﬁ-
cantly lower in the Df-treated mice compared to the 
178 Acta Med.  Okayama　Vol.  70,  No.  3Setiawan et al.
A Lung homogenate
Saline Df
XOR
β-tubulin
1.5
1.0
0.5
0.0
Saline Df
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
l
(fo
ld
 c
ha
ng
e)
B BALF
Saline Df
XOR
8
6
4
2
0
Saline Df
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
l
(fo
ld
 c
ha
ng
e)
＊＊＊
Fig. 1　 XOR expression in lung tissue and BALF.  XOR (150kD,  
upper),  β-tubulin (37kD,  lower),  and the relative expression level 
of XOR in lung homogenates (A) and BALF (B).  Data are the mean 
± SE of 5-6 mice in each group.  ＊＊＊ｐ＜0.001.
saline-treated mice (p＜0.01).  However,  no signiﬁcant 
diﬀerences were observed in the concentration of NO3－ 
in lung tissue between the saline- and Df-treated mice 
(Fig.  7A).  In the BALF,  no signiﬁcant diﬀerences 
were noted in the concentration of NO2－ or NO3－ 
between the saline- and Df-treated mice (Fig.  7B).
Discussion
　 Our previous studies demonstrated that intranasal 
Df exposure to NC/Nga mice can induce allergic air-
way inﬂammation,  which is characterized by airway 
restriction,  Th2 immune responses,  and airway 
remodeling.  This model is considered relevant to 
human asthma as it mimics allergen exposure in human 
and causes allergic airway inﬂammation (7,  8,  21,  
25,  26).
　 We herein demonstrated for the ﬁrst time an 
increase in XOR activity in Df-treated mice as well as 
changes in its localization from bronchial epithelial 
cells to the airway lumen in the Df-treated mouse lung.  
Diﬃculties were associated with diﬀerentiating between 
XOD and XDH immunohistochemically because the 
diﬀerence between XOD and XDH is only an intra-
molecular change of 2 cysteines in the disulﬁde bond 
[16].  However,  it is possible to distinguish between 
the enzymatic functions of XOD and XDH because 
XOD and XOR generate O2－ from O2 and uric acid 
from hypoxanthine,  whereas XDH generates uric acid 
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Fig. 3　 Zymography of XOD activity in lung tissue.  Intensity of 
the zymogram induced by the reduction of NBT with O2－ in the 
lungs of saline- and Df-treated mice.  Densitometric areas are 
expressed as the mean ± SE of 6-8 mice per group.  ＊ｐ＜0.05.
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Fig. 2　 Immunohistochemical staining of XOR in lung tissue.  
Immunostaining for XOR in saline-treated mice (A) and Df-treated 
mice (B).
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Fig. 4　 XDH activity by NADH formation.  Fluorescence data are 
expressed as nmol of NADH formation min－1 mg protein－1 from 6-8 
mice per group.
from hypoxanthine using NAD+ [27].
　 By using zymography to determine the activity of 
XOR,  we observed that O2－-generating activities and 
uric acid concentrations were higher in the Df-treated 
mice than in the saline-treated mice.  The conversion 
of the dehydrogenase form to the oxidase form of XOD 
may be promoted by the oxidative cleavage of the sul-
ﬁde bond by ROS.  Uric acid is metabolized from 
purines by XDH and XOR.  The high concentration of 
uric acid in the lungs of the Df-treated mice suggests 
that the oxidation of purines such as hypoxanthine to 
uric acid may be enhanced by XDH or XOD in 
Df-treated mice.  The XDH activity in the lungs was 
slightly lower in the Df-treated mice than in the 
saline-treated mice; thus,  the conversion of XDH to 
XOR may contribute to the generation of uric acid and 
O2－ by XOR.
　 In situ hybridization has been used to show the 
expression of mRNA for XOR in the lung as well was 
in the liver,  kidney,  gastrointestinal tract,  spleen,  
and heart of saline-treated mice [28].  The immunohis-
tochemical localization of XOR has been reported in 
hepatocytes and the bile duct [29],  and also in the 
mouse mammary gland [30].  In the present study,  the 
immunohistochemical localization of XOR in the lungs 
of saline-treated mice revealed that XOR was located 
in bronchial epithelial cells,  and may be released,  to 
some extent,  into the airway lumen.  Since XOR has 
the ability to generate ROS,  XOR in the bronchial 
epithelium and airway lumen may contribute to physi-
ological functions,  such as antimicrobial properties 
and host defenses through the generation of NO [18].
　 Elevated H2O2 concentrations have been reported 
in the exhaled breath condensates of asthmatic 
patients [31,  32].  In those studies,  H2O2 values in 
exhaled breath condensates were also determined in 
normal controls.  Therefore,  mechanisms may exist in 
airways for the generation of H2O2 under healthy 
conditions.  The H2O2 concentrations are high in 
exhaled breath condensates from Df-treated mice 
because the larger number of airway inﬂammatory 
cells such as activated macrophages and eosinophils 
generate O2－ in BALF; in addition,  the enhanced 
release of XOR may produce O2－ or H2O2.  We previ-
ously demonstrated that 8-hydroxy-2ʼ-deoxyguanosine 
(8-OHdG) concentrations were higher in the BALF of 
Df-treated mice,  and also that 8-OHdG concentrations 
and airway hyper-responsiveness in Df-treated mice 
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Fig. 6　 Hydrogen peroxide concentrations in lung tissue and 
BALF.  (A) Lung homogenates; (B) BALF.  Data are mean ± SE of 
6-8 mice per group.
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Fig. 5　 Uric acid concentrations in the lungs of the saline- and 
Df-treated mice.  Data are the mean ± SE of 6-8 mice per group.
were reduced by rebamipide,  a drug that scavenges 
O2－ and OH radicals [26].
　 Although we have not yet determined the origin of 
H2O2 in the airways of Df-treated mice,  XOR released 
from bronchial epithelial cells remains a possibility as 
the source of high H2O2 concentrations in BALF.  In 
addition,  the weaker staining for XOR in the bron-
chial epithelium of asthmatic lungs suggests an 
increase in the release of XOR into the alveolar 
lumen.  XOR activity as measured by western blotting 
and the concentration of H2O2 in BALF were higher 
in the present studyʼs Df-treated mice.  These results 
indicate that that the enhanced release of XOR into the 
BALF of Df-treated mice may generate H2O2.
　 As described above,  XOR has the capacity to 
generate NO under anoxic and acidic conditions [19,  
20].  In the present study,  a release-like appearance 
of XOR was observed by immunohistochemical analy-
sis in lungs.  If bronchial epithelial cells release XOR,  
it may contribute to increasing exhaled NO.  The 
increase in exhaled NO observed with asthma may be 
due to the up-regulation of NOS II [33] or NOS I 
[34].  However,  Zimmerman et al.  [35] demonstrated 
the up-regulation of arginase I in asthma,  and this up-
regulation of arginase I consumes a large amount of 
L-arginine,  a common substrate for arginase I and 
NOS,  resulting in the depletion of NO [5-8].  In the 
present study,  the decrease observed in NO2－ in the 
lungs of  the Df-treated mice supported the down-reg-
ulation of NO in the lungs with asthma,  as reported 
previously [36].  Therefore,  a discrepancy exists 
regarding the origin of increased exhaled NO in asthma.  
Our present ﬁndings suggests that the increased 
release of XOR in the airway lumen in asthma gener-
ates NO from NO2－ as a reductase [19,  20].
　 The results of the present study suggest that the 
enhanced activity of XOR and higher H2O2 concentra-
tions observed in the Df-treated mice may be associ-
ated with oxidative stress,  and they indicated that 
XOR,  which is released from the bronchial epithelium 
to the alveolar lumen in the asthmatic lung,  may con-
tribute to exhaled NO in asthma.  Further studies 
examining the inhibition of XOR activity are needed in 
order to elucidate the role of XOR in asthma.
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